Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116437 | 0.87 | PTGS2 (0.66) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL10119179 | 0.85 | PTGS2 (0.57) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4275929 | 0.84 | SMN1; SMN2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL5748928 | 0.84 | PTGS2 (0.55) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4267917 | 0.84 | PTGS2 (0.55) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL1429054 | 0.83 | PTGS2 (0.49) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL7228178 | 0.83 | GAA (0.62) | ALDH1A1MAPTSMN1; SMN2POLBGAA | |
| SCHEMBL25263044 | 0.82 | PTGS2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL5802629 | 0.82 | PTGS2 (0.54) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL14627365 | 0.82 | PTGS2 (0.54) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4334360-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Avilar Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117677399-A | Effective ASGPR binding compounds for the degradation of immunoglobulins and other proteins | 阿维拉治疗公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| CN-111183130-B | Benzoheterocycle derivatives and pharmaceutical compositions containing the same | 恒翼生物医药(上海)股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-8022218-B2 | Hypogonadism; N-{3-[2-Bromo-4-(3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydro-quinolin-4-yl)-6-ethoxy-phenoxymethyl]-phenyl}-3,4,5-trimethoxy-benzamide; low molecular weight hormone mimetics; selective Follicle Stimulating Hormone receptor agonists | N.V. ORGANON (NL) | 2011-09-20 | — | — | US | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | N.V. ORGANON (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1881830-B1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | ORGANON NV (NL) | 2008-10-08 | — | — | EP | disclosed |
| EP-1881830-A1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | N.V. Organon (NL) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006117368-A1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | N.V. ORGANON (NL) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | PTGS2 3229/4885ALDH1A1 3256/4885CYP2C9 3965/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | PTGS2 3229/4885ALDH1A1 3256/4885CYP2C9 3965/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | PTGS2 3229/4885ALDH1A1 3256/4885CYP2C9 3965/4885 |
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | CATSPER1, ABCB11, ACR | PTGS2 3105/4885ALDH1A1 79/4885CYP2C9 1289/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | PTGS2 3229/4885ALDH1A1 3256/4885CYP2C9 3965/4885 |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | PPARG, CDK5R1, CDK5 | PTGS2 733/4885ALDH1A1 4172/4885CYP2C9 3550/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PTGS2 1674/4885ALDH1A1 4575/4885CYP2C9 3963/4885 |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | PTGS2 3229/4885ALDH1A1 3256/4885CYP2C9 3965/4885 |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | PTGS2 1447/4885ALDH1A1 187/4885CYP2C9 62/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PTGS2 1674/4885ALDH1A1 4575/4885CYP2C9 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.